Free Trial

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

$39.53
+0.64 (+1.65%)
(As of 07/12/2024 ET)

Apellis Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$75.56
91.15% Upside
High Forecast$106.00
Average Forecast$75.56
Low Forecast$46.00
TypeCurrent Forecast
7/15/23 to 7/14/24
1 Month Ago
6/15/23 to 6/14/24
3 Months Ago
4/16/23 to 4/15/24
1 Year Ago
7/15/22 to 7/15/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
8 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$75.56$74.38$78.60$90.93
Forecasted Upside91.15% Upside41.11% Upside32.38% Upside40.83% Upside
Get Apellis Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

APLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

APLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Apellis Pharmaceuticals Stock vs. The Competition

TypeApellis PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.81
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside91.15% Upside994.16% Upside9.19% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$100.00 ➝ $100.00+159.54%
5/31/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Amin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$46.00+12.88%
5/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$92.00 ➝ $92.00+126.55%
5/23/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$57.00 ➝ $48.00+17.07%
5/8/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$67.00 ➝ $60.00+41.84%
5/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$89.00 ➝ $85.00+101.14%
5/8/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$85.00+93.62%
4/29/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$60.00 ➝ $52.00+4.29%
4/17/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$67.00 ➝ $57.00+15.76%
3/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$78.00 ➝ $79.00+29.49%
2/5/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$68.00 ➝ $80.00+27.88%
1/30/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$75.00 ➝ $79.00+20.78%
1/11/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetStrong-Buy ➝ Strong-Buy$67.00 ➝ $106.00+60.85%
1/9/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$65.00 ➝ $90.00+31.68%
12/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$52.00 ➝ $85.00+33.08%
8/29/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$60.00 ➝ $65.00+63.73%
11/8/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$45.00 ➝ $43.00-9.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 07:21 AM ET.

APLS Forecast - Frequently Asked Questions

What is Apellis Pharmaceuticals' forecast for 2024?

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Apellis Pharmaceuticals is $75.56, with a high forecast of $106.00 and a low forecast of $46.00.

Should I buy or sell Apellis Pharmaceuticals stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last year. There are currently 4 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" APLS shares.

Does Apellis Pharmaceuticals's stock price have much upside?

According to analysts, Apellis Pharmaceuticals's stock has a predicted upside of 48.30% based on their 12-month stock forecasts.

What analysts cover Apellis Pharmaceuticals?

Apellis Pharmaceuticals has been rated by research analysts at Citigroup, HC Wainwright, Mizuho, Needham & Company LLC, Piper Sandler, Robert W. Baird, UBS Group, Wedbush, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Apellis Pharmaceuticals more than its competitors?

Analysts like Apellis Pharmaceuticals more than other "medical" companies. The consensus rating score for Apellis Pharmaceuticals is 2.81 while the average consensus rating score for "medical" companies is 2.71. Learn more on how APLS compares to other companies.


This page (NASDAQ:APLS) was last updated on 7/14/2024 by MarketBeat.com Staff

From Our Partners